Abcellera Biologics Inc Financial Flexibility Index
Abcellera Biologics Inc financial flexibility index. Abcellera Biologics Inc (ABCL) has a Financial Flexibility Index of -0.08x as of June 2026. Free cash flow of $-31.73 Million (operating CF $-33.86 Million minus capex $2.13 Million) represents 0% of total liabilities ($411.56 Million). Explore Abcellera Biologics Inc capex to cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Abcellera Biologics Inc (2018–2025)
Financial flexibility index of Abcellera Biologics Inc from 2018 to 2025. Historical Financial Flexibility Index trend for Abcellera Biologics Inc across 8 annual periods. Check Abcellera Biologics Inc (ABCL) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Abcellera Biologics Inc Financial Flexibility Index by Year (2018–2025)
Abcellera Biologics Inc financial flexibility index by year from 2018 to 2025. Year-by-year free cash flow to debt coverage for Abcellera Biologics Inc. For the full cash flow conversion analysis, see ABCL cash generation efficiency.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.23x | $-88.52 Million | $-131.29 Million | $390.05 Million | ▼ -129.1% |
| 2024 | -0.10x | $-30.16 Million | $-108.56 Million | $304.47 Million | ▼ -198.9% |
| 2023 | 0.10x | $33.63 Million | $-43.88 Million | $335.78 Million | ▼ -91.2% |
| 2022 | 1.14x | $350.02 Million | $277.36 Million | $307.63 Million | ▲ +9.9% |
| 2021 | 1.03x | $303.04 Million | $244.58 Million | $292.84 Million | ▲ +384.8% |
| 2020 | 0.21x | $37.36 Million | $22.69 Million | $175.03 Million | ▼ -57.8% |
| 2019 | 0.51x | $6.69 Million | $2.69 Million | $13.24 Million | ▼ -43.7% |
| 2018 | 0.90x | $8.87 Million | $3.56 Million | $9.88 Million | — |